Expert Review of Clinical Pharmacology最新文献_第7页

Current and emerging pharmacotherapies for treating vascular malformations. 当前和新兴的治疗血管畸形的药物疗法。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-04-01 Epub Date: 2026-03-17 DOI: 10.1080/17512433.2026.2641807

Emmanuel Seront, An Van Damme, Julien Coulie, Laurence M Boon, Miikka Vikkula

{"title":"Current and emerging pharmacotherapies for treating vascular malformations.","authors":"Emmanuel Seront, An Van Damme, Julien Coulie, Laurence M Boon, Miikka Vikkula","doi":"10.1080/17512433.2026.2641807","DOIUrl":"10.1080/17512433.2026.2641807","url":null,"abstract":"Introduction: Vascular malformations are chronic, often progressive disorders for which conventional procedures frequently provide incomplete control. Advances in molecular genetics have revealed recurrent pathway alterations that now enable mechanism-based pharmacologic treatment.Areas covered: This narrative review summarizes current and emerging targeted therapies for vascular malformations, including mTOR, PI3K, MEK, anti-angiogenic, and genotype-specific inhibitors. Vascular malformations - capillary, lymphatic, venous, and arteriovenous - are increasingly recognized as disorders driven by dysregulation of the PI3K - AKT - mTOR and RAS - MAPK - ERK pathways, supporting rational repurposing of targeted anticancer drugs. We discuss clinical evidence, limitations, and practical considerations for sirolimus, PI3K inhibitors, thalidomide, MEK inhibitors, and KRAS-directed agents, as well as emerging combination and intermittent strategies to balance efficacy and toxicity. The review is based on a structured PubMed/MEDLINE search up to December 2025, prioritizing original translational studies, prospective trials, and large clinical series.Expert opinion: Targeted therapies are shifting management from procedure-centered to biology-guided care. Future progress depends on standardized molecular testing, patient-centered outcomes, and optimized treatment duration to achieve durable disease control with acceptable long-term toxicity.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"289-302"},"PeriodicalIF":3.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovation in pediatric atopic dermatitis care: examining emerging topical treatment options. 儿科特应性皮炎护理的创新：检查新兴的局部治疗方案。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-04-01 Epub Date: 2026-03-11 DOI: 10.1080/17512433.2026.2641800

Christina McGee, Alexander J Jafari, Adelaide A Hebert

{"title":"Innovation in pediatric atopic dermatitis care: examining emerging topical treatment options.","authors":"Christina McGee, Alexander J Jafari, Adelaide A Hebert","doi":"10.1080/17512433.2026.2641800","DOIUrl":"10.1080/17512433.2026.2641800","url":null,"abstract":"Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, eczematous lesions, and a relapsing course. The pathophysiology of atopic dermatitis involves an interplay of skin barrier dysfunction, immune dysregulation, genetic predisposition, environmental triggers, and alterations in the skin microbiome. Pediatric AD is frequently associated with allergic comorbidities and imposes a substantial psychosocial burden on affected children and their families. This manuscript will describe recent innovations in topical, steroid-sparing therapies for pediatric AD, highlighting emerging agents such as roflumilast, ruxolitinib, and tapinarof, as well as investigational therapies.Areas covered: PubMed and Clinicaltrials.gov were used to identify the latest advancements in topical therapies available for pediatric AD treatment, as of November 2025. First-line therapies include topical corticosteroids, topical calcineurin inhibitors, and the phosphodiesterase-4 inhibitor crisaborole, all of which have demonstrated efficacy but are limited by safety considerations, tolerability, and acceptability for long-term use. In recent years, novel topical agents with distinct mechanisms of action have expanded the therapeutic landscape, representing important steroid-sparing alternatives for children with AD.Expert opinion: Emerging topical therapies for pediatric AD demonstrate substantial promise in addressing longstanding unmet needs, but long-term safety and practice-based effectiveness data remain critical for optimizing care.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"303-311"},"PeriodicalIF":3.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147431861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A simulation study to assess the influence of population pharmacokinetic model selection on Bayesian forecasting of vancomycin exposure in preterm neonates. 评估群体药代动力学模型选择对早产儿万古霉素暴露贝叶斯预测影响的模拟研究。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-03-01 Epub Date: 2026-02-28 DOI: 10.1080/17512433.2026.2639035

Mehdi El Hassani, Mathieu Blouin, Van Dong Nguyen, Alexandre Duong, Amélie Marsot

{"title":"A simulation study to assess the influence of population pharmacokinetic model selection on Bayesian forecasting of vancomycin exposure in preterm neonates.","authors":"Mehdi El Hassani, Mathieu Blouin, Van Dong Nguyen, Alexandre Duong, Amélie Marsot","doi":"10.1080/17512433.2026.2639035","DOIUrl":"10.1080/17512433.2026.2639035","url":null,"abstract":"Background: Discrepancies in vancomycin AUC24 estimates across population pharmacokinetic (popPK) models raise concerns about their impact on dosing recommendations and probability of target attainment (PTA) after multiple therapeutic drug monitoring (TDM) occasions. This study assesses model selection's impact on model-based dosing and PTA following simulated TDM occasions and explores predictors of PTA.Research design and methods: Using a virtual neonatal population and 15 validated vancomycin popPK models, TDM events were simulated with initial dosing, followed by Bayesian-guided adjustments over three TDM occasions. The number of non-therapeutic patients was compared across models, and associations between model characteristics and simulated PTA were explored.Results: Across models, geometric mean (gMean) AUC24 values varied: 496 mg·h/L (35.7% geometric coefficient of variation, gCV) for the first TDM, 570 mg·h/L (53.1% gCV) for the second, and 484 mg·h/L (62.2% gCV) for the third. Non-therapeutic patients ranged from 0 (Mulubwa et al.) to 530 (Allegaert et al.). Interindividual variability in clearance correlated with non-therapeutic patients (R2 = 0.88), while residual variability showed no correlation.Conclusion: Model selection affects simulated vancomycin AUC24 values and PTA in neonates, influencing dosing decisions. These findings highlight model characteristics correlating with target attainment.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"275-287"},"PeriodicalIF":3.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147304334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the efficacy and tolerability of topical therapies for epidermolysis bullosa. 了解局部治疗大疱性表皮松解症的疗效和耐受性。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-03-01 Epub Date: 2026-03-08 DOI: 10.1080/17512433.2026.2641138

Sophie Andreou, Sera Sarsam, Dédée F Murrell

{"title":"Understanding the efficacy and tolerability of topical therapies for epidermolysis bullosa.","authors":"Sophie Andreou, Sera Sarsam, Dédée F Murrell","doi":"10.1080/17512433.2026.2641138","DOIUrl":"10.1080/17512433.2026.2641138","url":null,"abstract":"Introduction: Epidermolysis Bullosa (EB) is a group of rare inherited blistering disorders of the skin, characterized by fragile skin and mucous membranes. Topical therapies are central to symptom management and wound care, and recent advances provide potential for topical treatments to be disease-modifying approaches.Areas covered: This review examines the clinical efficacy and tolerability of topical therapies for EB, with a particular focus on approved treatments such as beremagene geperpavec (B-VEC) and Oleogel-S10, as well as emerging agents like allantoin, diacerein, sirolimus, gentamicin, gentian violet and calcipotriol. Using evidence from clinical trials and pilot studies, their mechanisms and outcomes can be evaluated for different EB subtypes.Expert opinion: Topical therapies for EB are evolving, with more gene-based treatments and anti-inflammatory agents showing potential for improving wounds, reducing pain and overall increasing quality of life. Challenges remain in trial designs, accessibility and long-term safety studies, especially in the context of the heterogeneity of EB. The continued use of standardized outcome measures will affect the future progress of studies, as well as using real-world data. Whilst a definitive cure is unlikely for EB, evolving topical strategies have strong potential in providing control of the disease's symptoms and ultimately can improve long-term outcomes.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"269-273"},"PeriodicalIF":3.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Could GUCY2C-targeted pharmacotherapy be effective in treating colorectal cancer? 靶向gucy2c的药物治疗能否有效治疗结直肠癌？

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-03-01 Epub Date: 2026-02-25 DOI: 10.1080/17512433.2026.2636120

Scott A Waldman, Adam E Snook

引用次数: 0

AI-enhanced therapeutic drug monitoring for vancomycin and β-lactam antibiotics in critical care: from population PK to bedside algorithms. 人工智能增强的万古霉素和β-内酰胺类抗生素在重症监护中的治疗药物监测：从人群PK到床边算法。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-03-01 Epub Date: 2026-03-02 DOI: 10.1080/17512433.2026.2638352

Ahmad Z Al Meslamani, Anan S Jarab, Eman Merghani Ali Mohammed

{"title":"AI-enhanced therapeutic drug monitoring for vancomycin and β-lactam antibiotics in critical care: from population PK to bedside algorithms.","authors":"Ahmad Z Al Meslamani, Anan S Jarab, Eman Merghani Ali Mohammed","doi":"10.1080/17512433.2026.2638352","DOIUrl":"10.1080/17512433.2026.2638352","url":null,"abstract":"Introduction: Although sepsis and other severe infections in intensive care are common and deadly, obtaining safe and effective exposure for vancomycin and broad-spectrum β-lactams is difficult because of substantial kinetic variability, operational difficulties with AUC-guided therapeutic drug monitoring (TDM) and model‑informed precision dosing (MIPD), and the limited effectiveness of current tools on patient-centered outcomes.Areas covered: This is a narrative review of exposure-response correlations, vancomycin and β-lactam kinetic targets, and the use of artificial intelligence (AI)-driven dosing tools and TDM/MIPD in patients in intensive care units (ICUs) and other high-acuity settings. From 2005 to 2025, we searched PubMed/MEDLINE, Embase, Web of Science, IEEE Xplore, and Google Scholar for English-language research, recommendations, and methodological publications on TDM, MIPD, AI, and machine learning (ML). This review summarized information on early AI-enabled clinical decision support systems, AUC-guided vancomycin TDM, β-lactam TDM in high-risk patients, and AI models that predict drug concentrations, AUC, acute kidney injury (AKI), and composite outcomes.Expert opinion: Most AI models are single-center, retrospective, and surrogate-focused. By incorporating validated AI components into multicentre procedures that prioritize explainability, data quality, usability, and prospective assessment, it has the greatest immediate advantage of enhancing guideline-aligned AUC-guided TDM and population pharmacokinetic (PopPK)//Bayesian frameworks.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"239-254"},"PeriodicalIF":3.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147316799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is marstacimab the next step in personalized and effective haemophilia management? 马司他单抗是血友病个性化和有效管理的下一步吗？

IF 3 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-03-01 Epub Date: 2026-03-09 DOI: 10.1080/17512433.2026.2636119

Johnny Mahlangu

引用次数: 0

Factor-VIII mimetic bispecific antibodies for the treatment of hemophilia A: an update. 治疗A型血友病的模拟因子- viii双特异性抗体：最新进展。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-03-01 Epub Date: 2026-03-09 DOI: 10.1080/17512433.2026.2636123

Vitória Eduarda Alves de Jesus, Douglas Lamounier de Almeida, Roberto Lúcio Muniz Júnior, Juliana Alvares-Teodoro, Glenn F Pierce, Ricardo Mesquita Camelo

{"title":"Factor-VIII mimetic bispecific antibodies for the treatment of hemophilia A: an update.","authors":"Vitória Eduarda Alves de Jesus, Douglas Lamounier de Almeida, Roberto Lúcio Muniz Júnior, Juliana Alvares-Teodoro, Glenn F Pierce, Ricardo Mesquita Camelo","doi":"10.1080/17512433.2026.2636123","DOIUrl":"10.1080/17512433.2026.2636123","url":null,"abstract":"Introduction: Bispecific antibodies are used to treat various conditions, with notable results in hemophilia A, a rare bleeding disorder characterized by reduced or absent activity of the coagulation factor VIII (FVIII). Emicizumab is a bispecific antibody that mimics FVIII activity, reducing bleeds in people with hemophilia A (PwHA). The real-world effectiveness and safety profile of emicizumab stimulated the development of additional FVIII-mimetic antibodies.Areas covered: This review covers recent progress in hemophilia A treatment, focusing on FVIII-mimetic bispecific antibodies. Emicizumab, the only currently approved FVIII-mimetic bispecific antibody, has shown effectiveness in reducing bleeding rates in PwHA with and without inhibitors, enabling improved musculoskeletal health and quality of life. Other FVIII-mimetic bispecific antibodies are in clinical trials (Mim8 and NXT007). We discuss mechanisms, preclinical and clinical outcomes, real-world data, safety, and new molecules expanding the therapeutic repertoire under development.Expert opinion: The advent of FVIII-mimetic bispecific antibodies marks a shift in hemophilia A prophylaxis away from FVIII replacement therapies. Next-generation agents may offer enhanced activity and safety. Despite advances, challenges remain in monitoring activity, managing breakthrough bleeds, and understanding non-hemostatic FVIII roles. As long-acting, subcutaneous agents mature, they may redefine care, enabling personalized, safer, and more accessible prophylaxis across the lifespan.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"219-238"},"PeriodicalIF":3.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147270239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictive biomarkers for immunotherapy response in ovarian cancer: the role of repair assisted damage detection (RADD). 卵巢癌免疫治疗反应的预测性生物标志物：修复辅助损伤检测（RADD）的作用。

IF 3 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-03-01 Epub Date: 2026-02-27 DOI: 10.1080/17512433.2026.2634795

Ilary Ruscito, Giorgia Russo, Adriana Ionelia Apostol, Marica Marraffa, Amedeo Cefaliello, Serena Maria Boccia, Carolina Maria Sassu, Anna Fagotti, Claudia Marchetti

引用次数: 0

Optimizing valganciclovir dosing strategies: a comprehensive review. 优化缬更昔洛韦给药策略：一项综合综述。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-03-01 Epub Date: 2026-03-03 DOI: 10.1080/17512433.2026.2640124

Kotaro Itohara, Ikuko Yano

{"title":"Optimizing valganciclovir dosing strategies: a comprehensive review.","authors":"Kotaro Itohara, Ikuko Yano","doi":"10.1080/17512433.2026.2640124","DOIUrl":"10.1080/17512433.2026.2640124","url":null,"abstract":"Introduction: Orally administered valganciclovir (VGCV) is rapidly metabolized to ganciclovir (GCV) and is used to prevent and treat cytomegalovirus (CMV) infection. Although GCV exposure is related to efficacy or toxicity, therapeutic drug monitoring (TDM) for GCV has not yet been clinically implemented. This review was conducted to summarize relevant current issues for implementing the optimization of VGCV therapy based on TDM.Areas covered: The current knowledge on the population pharmacokinetics of GCV after oral administration of VGCV, the relationships between GCV exposure with efficacy and toxicity, and the available evidence for TDM was comprehensively reviewed. The limited sampling strategy (LSS) and microsampling methods for clinically implementing TDM are summarized. The relationship between nucleoside-diphosphate-linked moiety X-type motif 15 (NUDT15) polymorphisms and toxicity is discussed. Relevant literature published before 2025 was searched in PubMed.Expert opinion: Accumulating evidence indicates that GCV exposure is associated with both efficacy and safety, and exposure-guided dosing (target area under the time-concentration curve (AUC) of 40-60 μg·h/mL) may provide a reliable approach for maximizing VGCV therapy. However, several methodological and practical challenges, including standardization of LSS and improvement of microsampling technologies, are required for practical VGCV dose optimization in all patient populations.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"255-267"},"PeriodicalIF":3.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147325127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0